Head-To-Head Contrast: NewAmsterdam Pharma (NASDAQ:NAMS) vs. PolyPid (NASDAQ:PYPD)

PolyPid (NASDAQ:PYPD) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Valuation & Earnings

This table compares PolyPid and NewAmsterdam Pharma”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17 million	($1.91)	-2.84
NewAmsterdam Pharma	$22.50 million	186.62	-$203.82 million	($1.79)	-20.07

PolyPid has higher earnings, but lower revenue than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares PolyPid and NewAmsterdam Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-241.96%	-126.91%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Insider & Institutional Ownership

26.5% of PolyPid shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

PolyPid has a beta of 1.4, indicating that its stock price is 40% more volatile than the S&P 500. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for PolyPid and NewAmsterdam Pharma, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1	0	4	0	2.60
NewAmsterdam Pharma	1	1	9	1	2.83

PolyPid currently has a consensus price target of $11.67, suggesting a potential upside of 115.25%. NewAmsterdam Pharma has a consensus price target of $49.00, suggesting a potential upside of 36.41%. Given PolyPid’s higher possible upside, equities analysts plainly believe PolyPid is more favorable than NewAmsterdam Pharma.

Summary

NewAmsterdam Pharma beats PolyPid on 8 of the 14 factors compared between the two stocks.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

About NewAmsterdam Pharma

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer’s disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.